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Abstract
Objective: The recent rise in ADHD has prompted concerns about adolescents with ADHD diverting and/or misusing
stimulants. This is the first study to assess physician perceptions of the pervasiveness of these issues. Method:
Questionnaires were mailed to a national sample of pediatric subspecialists. Responses were analyzed (n = 826; 18%
response rate) using descriptive statistics and regression analyses. Results: In the past year, 59% of physicians suspected
≥1 patient(s) with ADHD diverted stimulants. Seventy-four percent believed ≥1 patient(s) feigned symptoms to obtain
an initial ADHD diagnosis; 66% believed ≥1 patient(s) wanted stimulants to improve academic performance. Child and
adolescent psychiatrists were most likely to suspect diversion and feigning symptoms. Thirty-nine percent of physicians
believed diversion was at least “common.” Conclusion: Although many physicians suspected stimulant diversion and
misuse, a substantial number were unaware of these issues, and subspecialist perceptions varied. These findings support
the potential pervasiveness of these issues and the need for increased physician awareness. (J. of Att. Dis. 2020; 24(2)
290-300)
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Introduction
The American Academy of Pediatrics recognizes ADHD as
the most common childhood neurobehavioral disorder
(Subcommittee on Attention-Deficit/Hyperactivity Disorder
et al., 2011). Moreover, the percentage of children aged 4 to
17 diagnosed with ADHD has risen dramatically in recent
years, from 7.8% in 2003 to 9.5% in 2007 and finally to
11% in 2011 (Visser et al., 2014). Treatment plans for
ADHD often involve medication (Subcommittee on
Attention-Deficit/Hyperactivity Disorder et al., 2011), and
thus, a corresponding increase in prescriptions has also
been observed, with 6.1% of children taking some form of
ADHD medication in 2011 compared with only 4.8% in
2007 (Visser et al., 2014). Concerns have been raised
regarding the implications of a continued rise in ADHD and
stimulant prescriptions, particularly with the recent release
of the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-V; American Psychiatric
Association, 2013), which broadened the criteria for ADHD
diagnoses (Centers for Disease Control and Prevention,
2015). Increased availability of stimulant medication
among adolescents creates more opportunity for the illegal
diversion and unsafe misuse of these medications.
Using terminology as similarly defined by others (Wilens
et al., 2008), “diversion” refers to the exchange (selling or
giving away) of controlled medications, and “misuse” refers

to the use of a controlled medication either in a way that
was not prescribed or by a person who was not prescribed
the medication by a licensed health care provider. Stimulant
misuse and diversion in the adolescent population are problematic because of the associated health and legal consequences. The U.S. Drug Enforcement Administration
classifies stimulants such as amphetamines and methylphenidate as Schedule II–controlled substances with a high
potential for abuse and psychological or physical dependence (U.S. Department of Justice, n.d.). It is particularly
dangerous when individuals who are not prescribed these
medications misuse them, as their medical history may
make them more susceptible to adverse cardiovascular and/
or psychiatric side effects (Rabiner et al., 2009b; Shire,
2015). Aside from the health consequences of misuse, there
are also serious legal consequences if a person diverts his or
her stimulant medication, with punishments ranging from
fines to incarceration (CriminalDefenseLawyer, n.d.).
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These legal consequences may have greater detrimental
consequences than the immediate punishment, as studies
show that arrest during adolescence is associated with an
increased likelihood of dropping out of high school and
decreased likelihood of enrolling in a 4-year college, both
of which may lead to unemployment (Hjalmarsson, 2008;
Kirk & Sampson, 2013).
Recent evidence suggests that stimulant misuse and
diversion are prevalent in both the adolescent (Cottler,
Striley, & Lasopa, 2013; McCabe, Teter, & Boyd, 2004;
McCabe & West, 2013; McCauley et al., 2010; Poulin, 2001,
2007; Viana et al., 2012; Wilens et al., 2008) and collegeaged populations (DeSantis, Webb, & Noar, 2008; GarnierDykstra, Caldeira, Vincent, O’Grady, & Arria, 2012; K. M.
Hall, Irwin, Bowman, Frankenberger, & Jewett, 2005; Low
& Gendaszek, 2002; McCabe & Boyd, 2005; Rabiner, 2013;
Rabiner et al., 2009a; Singh, Bard, & Jackson, 2014; Teter,
McCabe, LaGrange, Cranford, & Boyd, 2006; White,
Becker-Blease, & Grace-Bishop, 2006; Wilens et al., 2008).
One specific study examining non-medical use of stimulants
among adolescents found that 2.0%, 8.2%, 9.0%, and 14.1%
of students in grades 7, 9, 10, and 12, respectively, reported
misusing amphetamines, and 2.2%, 7.6%, 7.4%, and 7.3%
in the same corresponding grades reported non-medical use
of methylphenidate (Poulin, 2007). Reports also suggest that
many non-ADHD students who misuse stimulants obtain
them from peers with ADHD who divert their medication
(Garnier-Dykstra et al., 2012; McCabe & Boyd, 2005;
McCabe et al., 2004; McCabe et al., 2011; Poulin, 2001,
2007; Rabiner, 2013; Wilens et al., 2008). In one study,
approximately 26% of adolescents who were prescribed
methylphenidate reported diverting their medication in the
past month (Poulin, 2007). In addition, there has been speculation that some young adults are feigning ADHD symptoms
to obtain stimulants—in essence, attempting to receive prescriptions for stimulants directly from physicians for misuse
(Rabiner, 2013). It has also been suggested that physicians
may increasingly encounter patients explicitly seeking medication for cognitive neuroenhancement (Larriviere,
Williams, Rizzo, & Bonnie, 2009).
To prevent the illegal diversion and potentially unsafe
misuse of prescription stimulants, it is important to further
evaluate this issue from a physician’s perspective. Although
the literature provides evidence that stimulant misuse and
diversion among adolescents are issues of concern, there is
a lack of studies that evaluate physician perceptions of these
issues. To date, only three studies have evaluated physician
concerns regarding prescription stimulant misuse and/or
diversion. Stockl, Hughes, Jarrar, Secnik, and Perwien
(2002) found that 19% of physicians were concerned about
diversion when prescribing a controlled medication for
ADHD. However, other than “concern,” this study did not
ask any further questions regarding diversion of these medications. In addition, this study was geographically restricted

to four states and was published more than 10 years ago.
The second study, published in 2003, investigated family
practitioner concerns when prescribing stimulants
(Hellerstein & Biedermann, 2003). Physicians rated “abuse
potential” as their highest concern when prescribing methylphenidate (tied with “adverse effects”), with a mean score
of 3.3 out of 5 (where 1 denoted “never a concern” and 5
denoted “always a concern”), but there were no further
questions about stimulant misuse. Finally, a 2004 survey
found that only 25.3% of physicians were very confident in
their ability to recognize when a person was attempting to
obtain controlled medications for abuse and/or diversion;
however, this unpublished study was focused neither on
ADHD as a disorder nor on pediatric providers (The
National Center on Addiction and Substance Abuse at
Columbia University, 2005).
This study assesses physician perceptions of the pervasiveness of ADHD stimulant diversion and misuse among
their own adolescent patients and in general. Furthermore,
this study focuses on a national sample of the three pediatric
subspecialists with the greatest clinical focus on ADHD:
child and adolescent psychiatrists (CAP), child neurologists
(CN), and developmental–behavioral pediatricians (DBP).
A better understanding of the perceptions of pediatric subspecialists regarding stimulant diversion and misuse will
provide an important addition to the current literature on the
potential pervasiveness of stimulant diversion and misuse,
as recent studies mostly focus on prevalence estimates
through self-report by adolescents. In addition, this study
will help to elucidate physician awareness of an important
issue pertaining to adolescents with ADHD.

Method
Study Design
A questionnaire focused on stimulant diversion and misuse
by high-school students was developed and mailed to three
groups of pediatric subspecialists in the United States: CAP,
CN, and DBP. In addition to the questionnaire and a cover
letter explaining implied consent and the voluntary nature
of the study, the mailing included several participation
incentives: a laminated ADHD Medication Guide and the
opportunity to request educational materials on stimulant
misuse and diversion, a Teen Fact Sheet to share with their
patients with ADHD, and up to three additional copies of
the ADHD Medication Guide.
The questionnaires were mailed in August 2013, and
responses were received between August 2013 and May
2014. Mailing labels for CAP and CN were obtained from
the American Medical Association. Questionnaires were
sent to 3,021 CAP who were identified using the selection
criteria “Primary Specialty: Child Psychiatry” and “Board
Certification: Child & Adolescent Psychiatry,” and 907 CN
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who were identified using the selection criteria of “Primary
Specialty: Child Neurology” and “Board Certification:
Neurology With Special Qualifications in Child Neurology.”
Mailing labels for DBP were obtained from the Society for
Developmental and Behavioral Pediatricians, and questionnaires were sent to 579 DBP who were members of this
society. In total, questionnaires were sent to 4,507 physicians. The study received approval from the North ShoreLong Island Jewish Institutional Review Board.

Measures
In addition to soliciting information regarding physician
demographics, the four-page questionnaire assessed physician perceptions of the pervasiveness of stimulant diversion
and misuse, knowledge and training regarding these issues,
and clinical practices to prevent stimulant diversion.

Data Analysis
Distributional assumptions of all variables were checked
using histograms, q-q plots, and Shapiro–Wilks tests before
conducting statistical analyses. Differences in sample characteristics between groups were examined using chi-square
analysis for categorical variables. Bivariable and multivariable (log-binomial) regression analyses (risk ratios [RR])
were carried out to identify differences between subspecialists regarding perceptions of stimulant diversion in their
patients with ADHD and in general, perceptions of patients
exaggerating and feigning ADHD symptoms, and perceived
motivations of patients who were suspected of feigning
ADHD symptoms, with adjusted risk ratios (aRR) reflecting
adjustment for the following three confounders identified a
priori: physician gender, physician stimulant prescribing volume, and recency of subspecialty training (except when these
were effect measure modifiers) (McNutt, Wu, Xue, & Hafner,
2003). Effect measure modification was examined using
interaction terms in regression models, and stratified effect
estimates were reported for variables found to be effect measure modifiers (p < .2; Rothman & Greenland, 1998).
Bivariable and multivariable (log-binomial) regression models were also used to examine the association between physician perceptions of how frequently their own patients divert
their stimulant medication and how common they believed
this practice to be in general. Regression models involving
physician perceptions of their own patients used a threshold
of suspecting at least one patient of improper behavior with
regard to their stimulants in the past year. All analyses were
performed using SAS (version 9.3) statistical software.

Results
In total, 894 health care professionals completed questionnaires, but only responses from pediatric subspecialists who
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currently prescribe stimulant medications and whose subspecialty was clearly identifiable were included in the analysis. The final sample consisted of 826 physicians: 579
CAP, 106 CN, and 141 DBP, with an overall response rate
of 18%. Physicians in 49 states were represented in the sample, with a mean medical school graduation date of 1991
(SD = 10; range = 1957-2012). By subspecialty, CAP had a
mean graduation date of 1992 (SD = 8; range = 1974-2012);
CN, 1987 (SD = 12; range = 1959-2007); and DBP, 1986
(SD = 12; range = 1957-2010). Table 1 includes additional
sample demographics.

Physician Perceptions of Diversion and
Exaggerated Symptoms by ADHD Patients
In the past 12 months, 59% of all physicians suspected at
least one of their high-school patients with ADHD diverted
stimulant medication to others and 10% of all physicians
suspected five or more patients had diverted their medication. Perceptions differed by subspecialty (Table 2).
Compared with other subspecialists, CAP were most likely
to suspect diversion; 69% suspected one or more patients of
selling or giving away their stimulant medication. Only
42% of CN suspected diversion by at least one patient and
were much less likely to suspect diversion compared with
CAP, even when controlling for gender, prescribing volume, and recency of subspecialty training (aRR = 0.68;
95% confidence interval [CI] = [0.54, 086]). DBP were also
less likely to suspect diversion compared to CAP, and gender was found to be a significant effect measure modifier;
more male DBP suspected diversion than female DBP, even
when controlling for prescribing volume and recency of
subspecialty training.
Overall, 53% of all pediatric subspecialists suspected
one or more patients with ADHD exaggerated symptoms in
the past year to obtain more stimulants for misuse or diversion, and 12% of physicians suspected five or more patients
had exaggerated their symptoms for this purpose. As shown
in Table 2, 62% of CAP suspected at least one patient of
exaggerating symptoms and were again most likely to suspect this behavior compared with other subspecialists. CN
were 20% less likely to suspect patients of exaggerating
symptoms compared with CAP when controlling for the
three confounders. DBP, in general, were also less likely to
suspect improper behavior of patients, and again, gender
was found to be a significant effect measure modifier: 33%
of male DBP suspected patients of exaggerating symptoms,
compared with only 20% of female DBP.
Prescribing volume was found to be an effect measure
modifier when evaluating subspecialty differences in perceptions, but only with regard to perceptions of patients
diverting stimulants (Table 3). Differences among subspecialists were most pronounced among “low-volume” prescribers (currently prescribe stimulants to 1-10 patients);
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Table 1. Demographics of Physician Sample.
Total
(n = 826)
n (%)

CAP
(n = 579)
n (%)

CN
(n = 106)
n (%)

DBP
(n = 141)
n (%)

Genderb
Male
369 (45%)
255 (44%)
61 (58%)
53 (38%)
Female
456 (55%)
324 (56%)
44 (42%)
88 (62%)
For approximately how many high-school students with ADHD do you currently prescribe stimulant medication?
1-10 patients
158 (19%)
101 (17%)
24 (23%)
33 (23%)
(Low volume)
11-30 patients
245 (30%)
158 (27%)
36 (34%)
51 (36%)
(Medium volume)
>30 patients
423 (51%)
320 (55%)
46 (43%)
57 (40%)
(High volume)
How many years ago did you complete your subspecialty training?c
<5
122 (15%)
87 (15%)
14 (13%)
21 (16%)
5-15
313 (38%)
252 (44%)
32 (31%)
29 (22%)
16-30
335 (41%)
237 (41%)
37 (35%)
61 (46%)
>30
45 (6%)
1 (0.2%)
22 (21%)
22 (17%)

p valuea
<.01

.01

<.01

Note. CAP = child and adolescent psychiatrists; CN = child neurologists; DBP = developmental and behavioral pediatricians.
a
Chi-square comparisons were performed to assess three-way differences between CAP, CN, and DBP.
b
Missing data from one respondent.
c
Missing data from 11 respondents.

Table 2. Physician Perceptions of Stimulant Diversion and Misuse Among Their Own Patients.
In the past 12 months, how many of your high school–
age patients with ADHD have you suspected were
selling or giving their stimulant medication to others?
0

>1

182 (31%)
61 (58%)

397 (69%)
45 (42%)

98 (70%)

43 (30%)

Male DBP

29 (55%)

24 (45%)

Female DBP

69 (78%)

19 (22%)

Total (N = 826)

341 (41%)

485 (59%)

CAP
CN

c

DBP

RR
[95% CI]

aRRb
[95% CI]

—
0.62
[0.49, 0.78]
0.45
[0.34, 0.57]
0.66
[0.49, 0.90]
0.32
[0.21, 0.47]

—
0.68
[0.54, 0.86]
N/A
0.75
[0.55, 0.98]
0.34
[0.23, 0.51]

In the past 12 months, how many of your high school–
age patients with ADHD have you suspected were
exaggerating their present ADHD symptoms to get
more stimulants for misuse or diversion?a
0

>1

219 (38%)
61 (58%)

360 (62%)
45 (42%)

105 (75%)

35 (25%)

35 (67%)

17 (33%)

70 (80%)

18 (20%)

385 (47%)

440 (53%)

RR
[95% CI]

aRRb
[95% CI]

—
0.68
[0.54, 0.86]
0.40
[0.30, 0.54]
0.56
[0.37, 0.83]
0.32
[0.21, 0.48]

—
0.80
[0.64, 0.9981]
N/A
0.68
[0.53, 0.99]
0.36
[0.23, 0.55]

Note. RR = risk ratio; CI = confidence interval; CAP = child and adolescent psychiatrists; CN = child neurologists; DBP = developmental–behavioral
pediatricians.
a
Missing data from one respondent.
b
Adjusted risk ratios (aRR) included variables for physician gender (except for DBP), prescribing volume, and recency of subspecialty training. Gender
was an effect measure modifier for DBP only; one respondent was missing data for gender.
c
CAP subspecialists were considered the reference group in these analyses.
All risk ratios in bold are statistically significant.

compared with CAP, CN were 94% less likely and DBP
were 98% less likely to suspect patients of diverting their
stimulants when controlling for gender and recency of subspecialty, although the number of physicians in some

categories was small. Among “medium-volume” (currently
prescribe stimulants to 11-30 patients) and “high-volume”
(currently prescribe stimulants to >30 patients) prescribers,
DBP were again less likely to suspect stimulant diversion
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Table 3. Physician Perceptions of Stimulant Diversion With Prescribing Volume as an Effect Measure Modifier.
In the past 12 months, how many of your high school–age patients with ADHD have you suspected
were selling or giving their stimulant medication to others?

Low-volume prescribersb
CAPc
CN
DBP
Medium-volume prescribersd
CAPc
CN
DBP
High-volume prescriberse
CAPc
CN
DBP
Total (N = 826)

0

>1

RR [95% CI]

aRRa [95% CI]

53 (52%)
22 (92%)
32 (97%)

48 (48%)
2 (8%)
1 (3%)

—
0.18 [0.05, 0.67]
0.06 [0.01, 0.44]

—
0.06 [0.01, 0.58]
0.02 [0.00, 0.12]

57 (36%)
19 (53%)
37 (73%)

101 (64%)
17 (47%)
14 (27%)

—
0.74 [0.51, 1.06]
0.43 [0.27, 0.68]

—
0.90 [0.64, 1.29]
0.47 [0.29, 0.76]

72 (23%)
20 (43%)
29 (51%)
341 (41%)

248 (78%)
26 (57%)
28 (49%)
485 (59%)

—
0.73 [0.56, 0.95]
0.63 [0.48, 0.83]

—
0.77 [0.59, 1.01]
0.68 [0.51, 0.90]

Note. RR = risk ratio; CI = confidence interval; CAP = child and adolescent psychiatrists; CN = child neurologists; DBP = developmental–behavioral
pediatricians;
a
Adjusted risk ratios (aRR) included variables for physician gender and recency of subspecialty training; one respondent was missing data for gender.
b
Low-volume prescribers currently prescribe stimulants to 1 to 10 adolescent patients.
c
CAP subspecialists were considered the reference group in these analyses.
d
Medium-volume prescribers currently prescribe stimulants to 11 to 30 adolescent patients.
e
High-volume prescribers currently prescribe stimulants to >30 adolescent patients.
All risk ratios in bold are statistically significant.

compared with CAP, albeit to a lesser extent than among
“low-volume” prescribers. CN perceptions, in contrast,
were not significantly different from CAP perceptions
when controlling for gender and recency of subspecialty
training.
Notably, 35% of physicians who currently treat 11 or
more high-school patients with stimulants did not suspect
diversion among any of their patients in the past year (46%:
medium-volume prescribers; 29%: high-volume prescribers). Furthermore, among physicians who currently prescribe stimulants to more than 30 patients, 85% of physicians
did not suspect diversion by five or more patients with
ADHD in the past year. In addition, 42% of physicians who
treat 11 or more patients with stimulants did not suspect
even one patient of exaggerating symptoms to obtain more
stimulants for misuse and/or diversion (55%: medium-volume prescribers; 34%: high-volume prescribers). Among
physicians who currently prescribe stimulants to more than
30 patients, 82% did not suspect five or more patients of
exaggerating symptoms to obtain more stimulants.

Physician Perceptions of Patients Feigning ADHD
Symptoms
In the past 12 months, 74% of physicians suspected that one
or more high-school students who presented in the past year
for an initial diagnosis of ADHD had feigned symptoms to

obtain stimulants, and 28% suspected four or more patients
had done so. Table 4 shows further subspecialist differences
in perceptions. Although 82% of CAP believed one or more
patients feigned ADHD symptoms, CN were less likely to
have this perception compared with CAP when controlling
for gender, prescribing volume, and recency of subspecialty
training (aRR = 0.76; 95% CI = [0.64, 0.90]). DBP were
also less likely to suspect at least one patient of feigning
ADHD symptoms, and gender played a significant role in
DBP perceptions. Whereas male DBP were 27% less likely
to suspect a patient of feigning ADHD symptoms compared
with CAP when controlling for potential confounders,
female DBP were 47% less likely to have this perception.
With regard to the specific presumed motivations of
patients who were suspected to be feigning ADHD symptoms, 66% of physicians believed at least one patient
sought stimulants to improve their academic performance,
40% to lose weight, 39% to divert stimulant medication to
others, and 37% to get high. CAP were most likely to suspect at least one patient of feigning symptoms for each
reason, compared with both CN and DBP. However, gender was again found to modify associations between subspecialty and perceptions. Effect estimates for female
DBP were consistently below and farther from the null
than male DBP.
It should be noted that 22% of physicians who currently
prescribe stimulants to 11 or more patients did not suspect any
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106
(18%)
39
(38%)
69
(50%)
21
(40%)
48
(56%)
214
(26%)

473
(82%)
65
(63%)
69
(50%)
32
(60%)
37
(44%)
607
(74%)

>1
—

aRRf
[95% CI]
0

162
(29%)
0.77
0.76
42
[0.66, 0.89] [0.64, 0.90] (40%)
0.61
N/A
72
[0.52, 0.73]
(52%)
0.77
0.73
22
[0.62, 0.97] [0.56, 0.96] (42%)
0.51
0.53
50
[0.40, 0.66] [0.41, 0.68] (59%)
276
(34%)

—

RR
[95% CI]
406
(71%)
62
(60%)
66
(48%)
31
(58%)
35
(41%)
534
(66%)

>1

0.83
[0.71, 0.99]
0.67
[0.56, 0.80]
0.84
[0.66, 1.06]
0.57
[0.44, 0.74]

—

RR
[95% CI]
0

290
(52%)
0.83
71
[0.69, 0.998] (70%)
N/A
112
(85%)
0.78
39
[0.58, 1.03] (81%)
0.59
73
[0.45, 0.77] (88%)
473
(60%)

—

aRRf
[95% CI]

Academic improvementb

266
(48%)
31
(30%)
19
(15%)
9
(19%)
10
(12%)
316
(40%)

>1

0.64
[0.47, 0.86]
0.30
[0.20, 0.46]
0.45
[0.25, 0.83]
0.23
[0.13, 0.41]

—

RR
[95% CI]

Weight lossc

0.48
[0.25, 0.94]
0.22
[0.12, 0.40]

0.62
[0.44, 0.89]
N/A

—

aRRf
[95% CI]
292
(53%)
74
(73%)
116
(89%)
40
(83%)
76
(92%)
482
(61%)

0
261
(47%)
28
(27%)
15
(11%)
8
(17%)
7
(8%)
304
(39%)

>1

0.58
[0.42, 0.81]
0.24
[0.15, 0.39]
0.39
[0.21, 0.75]
0.17
[0.08, 0.34]

—

RR
[95% CI]

Diversiond

0.42
[0.21, 0.85]
0.19
[0.09, 0.40]

0.68
[0.49, 0.95]
N/A

—

aRRf
[95% CI]

289
(52%)
84
(83%)
120
(91%)
43
(88%)
77
(93%)
493
(63%)

0

265
(48%)
17
(17%)
12
(9%)
6
(12%)
6
(7%)
294
(37%)

>1

0.35
[0.23, 0.55]
0.19
[0.11, 0.33]
0.27
[0.13, 0.59]
0.14
[0.07, 0.31]

—

RR
[95% CI]

Getting highe

0.32
[0.15, 0.69]
0.15
[0.06, 0.35]

0.36
[0.22, 0.58]
N/A

—

aRRf
[95% CI]

b

a

Note. RR = risk ratio; CI = confidence interval; CAP = child and adolescent psychiatrists; CN = child neurologists; DBP = developmental–behavioral pediatricians.
Missing data from five respondents.
Missing data from 16 respondents.
c
Missing data from 37 respondents.
d
Missing data from 40 respondents.
e
Missing data from 39 respondents.
f
Adjusted risk ratios (aRR) included variables for physician gender (except for DBP), prescribing volume, and recency of subspecialty training. Gender was an effect modifier for DBP only; one respondent was missing data for gender.
g
CAP subspecialists were considered the reference group in these analyses.
All risk ratios in bold are statistically significant.

Male
DBP
Female
DBP
Total
(N = 826)

DBP

CN

CAPg

0

Any reason
(aggregate of responses)a

In the past 12 months, how many times have you suspected that a high-school student was complaining of ADHD symptoms so that he or she could get an initial diagnosis of ADHD in order to get stimulant medication
for the purpose of:

Table 4. Physician Perceptions of Patients Feigning ADHD Symptoms to Obtain Stimulants for Non-Medical Purposes.
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patients of feigning ADHD symptoms (28%: medium-volume
prescribers; 19%: high-volume prescribers). Furthermore,
among physicians who currently prescribe stimulants to more
than 30 patients, 48% did not suspect four or more patients
had feigned symptoms in the past year.

Physician Perceptions of Stimulant Diversion in
General
Overall, 39% of physicians believed it was “common” or
“very common” for high-school students with ADHD to
divert stimulant medication to peers. By subspecialty, 41% of
CAP, 27% of CN, and 40% of DBP thought stimulant diversion was “common” or “very common.” CN were 36% less
likely to have this perception compared with CAP when controlling for potential confounding factors including physician
gender, prescribing volume, and recency of subspecialty
training (aRR = 0.64; 95% CI = [0.44, 0.93]). Gender was
found to be an effect modifier for DBP; 43% of male DBP
and 39% of female DBP believed stimulant diversion was at
least “common.” Male DBP and female DBP were each as
likely to perceive stimulant diversion as common as CAP
when controlling for confounding variables including prescribing volume and recency of subspecialty training (male
DBP: aRR = 1.43; 95% CI = [0.94, 2.15] and female DBP:
aRR = 0.79; 95% CI = [0.58, 1.09]). Physician responses of
“not sure” (n = 33) were excluded from this analysis.
Physicians who did not suspect any of their patients of
diverting their stimulant medication were more likely to
believe this practice was not “common” or “very common”
in general (RR = 1.37; 95% CI = [1.13, 1.65]). Prescribing
volume was not a significant confounder in this analysis.

Discussion
This is the first study to provide evidence that many pediatric subspecialists suspect stimulant diversion and misuse in
their high-school patients with ADHD. More than half of
physicians in this study suspected one or more of their own
patients with ADHD sold or gave away their stimulants, and
that one or more of their patients exaggerated symptoms to
obtain more stimulants for misuse or diversion. Although
we cannot make any conclusions regarding the accuracy of
physician suspicions, these findings suggesting the potential pervasiveness of stimulant diversion are supported by
previous research showing that a significant number of adolescents with ADHD divert their medication. One study in
particular found that more than a quarter of middle- and
high-school students had diverted their prescribed stimulant
medication (Poulin, 2007).
Almost three fourths of physicians in this study believed
one or more of their patients in the past 12 months feigned
symptoms to obtain an initial ADHD diagnosis to receive
stimulants for non-medical use. These perceptions reflect a
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growing concern regarding students feigning ADHD symptoms (Rabiner, 2013). One recent study similarly found
that almost 50% of students at one college who self-referred
for an ADHD evaluation were suspected of exaggerating
symptoms and/or dishonestly completing a neurological
assessment in an effort to receive stimulant medication
(Sullivan, May, & Galbally, 2007). Another study reported
that almost 20% of individuals without ADHD who misused stimulants in the past year had obtained fraudulent
prescriptions from physicians (Novak, Kroutil, Williams,
& Van Brunt, 2007). This current study—focused on perceptions of pediatric subspecialists—provides additional
evidence that young people may be trying to obtain stimulants for illicit purposes through legal means (i.e., from
health care providers).
Most physicians in our sample suspected students of trying to obtain stimulant medication specifically to improve
their academic performance. This finding is consistent with
previously published investigations reporting that studying
and improved concentration are the most common reasons
for which students misuse stimulants (DeSantis et al., 2008;
Garnier-Dykstra et al., 2012; Teter et al., 2006). DeSantis
et al. (2008) found that 72% of students who reported illicitly using ADHD stimulants were doing so to stay awake to
study longer, and 66% were doing so to concentrate on
work. To a lesser extent, physicians in our study believed
students were seeking stimulants for diversion, getting
high, and weight loss. These perceptions are also supported
by the DeSantis et al. study, in which a minority of students
cited their motivation for stimulant misuse as “for the high
(the good feeling)” (7%) or to suppress appetite (5%)
(DeSantis et al., 2008).
Although physicians seem mindful of the different reasons for which patients might feign ADHD symptoms to
obtain stimulants, it is important to note that we cannot validate the accuracy of physician suspicions through this study
design. Furthermore, although many physicians in our sample suspected one or more patients of feigning symptoms to
obtain a false diagnosis of ADHD, one recent study emphasized that most students who misuse stimulants obtained
them from peers with ADHD, not from physicians as treatment for feigned symptoms (Arria & DuPont, 2010).
Physicians who evaluate adolescents for a new diagnosis of
ADHD are in a difficult position. On one hand, they must be
vigilant to the possibility that a patient may be feigning
ADHD symptoms to obtain stimulants; on the other hand,
they must also recognize that some students with significant
inattention may not present for clinical evaluation and treatment until adolescence.
Although most physicians in our sample suspected at
least one patient of diverting stimulants or feigning ADHD
symptoms in the past year, it is noteworthy that a sizable
number of physicians did not suspect any of their patients of
improper behavior with regard to their stimulants.
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Furthermore, the vast majority of physicians in our sample
did not suspect five or more patients of diverting their stimulants. Although we cannot confirm the accuracy of physician suspicions, these results suggest a potential lack of
awareness by physicians regarding stimulant misuse and/or
diversion. This seeming lack of awareness is especially
apparent among physicians who prescribe stimulants to
many patients; a third of physicians who currently prescribe
stimulants to more than 30 high-school patients with ADHD
did not suspect even one of their patients had diverted their
medication in the past year, and 85% of these high-volume
prescribers did not suspect five or more patients had
diverted stimulants.
In addition, almost 60% of physicians in our sample did
not perceive stimulant diversion to be common or very
common overall. An association was noted in this study
between physician perceptions of stimulant diversion
among their own patients and physician perceptions of
diversion in general, although it is unclear which perception
influenced the other because neither causality nor directionality can be inferred. Although the word “common” is
imprecise and may be interpreted differently by individual
respondents, this finding nevertheless also suggests a lack
of physician awareness of these issues given the documented prevalence of stimulant diversion and misuse in the
adolescent population (Poulin, 2007; Wilens et al., 2008).
As noted in previous research, there is a need for heightened
physician awareness of misuse and diversion of prescription stimulants (Arria & DuPont, 2010), potentially through
increased medical education on these issues.
Another major study finding is that subspecialists differed
in their perceptions of the pervasiveness of stimulant diversion and misuse. CAP were most likely to suspect their own
patients of diverting stimulants or exaggerating symptoms, as
well as feigning symptoms to obtain an initial ADHD diagnosis, while CN and DBP were less suspicious of their patients.
However, when asked about the general prevalence of stimulant diversion, a similar percentage of CAP and DBP believed
this to be common or very common among adolescents; CN
were less likely to identify with this view.
Confounding factors may help to explain differences in
perceptions of subspecialists. Physician prescribing volume
was found to be a significant covariate, but only with regard
to patients selling or giving their stimulants to others.
Observed differences by subspecialty were magnified
among low-volume prescribers and narrowed among highvolume prescribers. Low-volume prescribers may suspect
diversion less often because they have a smaller sample of
patients and/or less experience treating ADHD.
In addition, gender consistently modified DBP perceptions; male DBP were more likely to suspect their own
patients of improper behavior involving stimulants.
Research shows that patients tend to communicate more
positive statements to female physicians (J. A. Hall & Roter,
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2002), and patients may be less willing to disclose stimulant
diversion and misuse to female physicians in an effort to
maintain positive rapport. However, it remains unclear why
this significant gender difference was only observed among
DBP in this study.
Prescribing volume, gender, and recency of subspecialty
training—although important covariates to consider—do not
fully explain subspecialist differences. Differences in patient
populations may also contribute to these differences in subspecialist perceptions. For instance, CAP may suspect stimulant diversion or misuse more frequently among their patients
because they are more likely to treat adolescents with conduct disorder and substance use disorder. Research suggests
that these patients are more likely to misuse and divert stimulants; Wilens, Gignac, Swezey, Monuteaux, and Biederman
(2006) found that every ADHD participant who reported
diverting prescription stimulants had comorbid conduct disorder and/or substance use disorder, and 83% of ADHD participants who reported misusing their medication met criteria
for at least one of these two comorbid disorders.
It is important to consider ways in which physicians can
work to prevent these illegal and potentially dangerous
activities. As suggested in several studies, physicians are in
a unique position as prescribers of stimulant medication to
prevent stimulant misuse and diversion (Arria & DuPont,
2010; Garnier et al., 2010). First, physicians can better educate themselves about the consequences of stimulant misuse and/or diversion and the clinical signs that a patient
might be engaging in these activities. It is encouraging that
many physicians in our sample requested the educational
materials about stimulant misuse that were offered as an
incentive for participation in this study. Hopefully, these
educational materials will not only enable physicians to better inform their patients with ADHD regarding stimulant
misuse and diversion, but also prompt an ongoing dialogue
regarding these issues during the course of their treatment.
Physicians can also adopt specific prevention practices:
using medication contracts (i.e., written agreements that
commit the patient to adhering to a specified treatment plan
and medication regimen), employing pill counts (i.e., counting the number of pills that patients have taken at the end of
the month to measure adherence), distributing print materials about stimulant misuse and diversion, and prescribing
long-acting stimulants or non-stimulants instead of immediate-release stimulants, as immediate-release stimulants
have a higher potential for abuse (Levin, Evans, & Kleber,
1999; The National Center on Addiction and Substance
Abuse at Columbia University, 2005). Furthermore, if physicians suspect stimulant misuse among particular patients,
they should consider referring these patients for counseling
and/or substance abuse treatment.
However, although physicians should be encouraged to
implement practices designed to prevent and address stimulant misuse and diversion, they should also be cognizant of
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potential biases toward certain populations (e.g., a belief that
patients with a substance use history may be misusing stimulants) and should be aware that their suspicions may ultimately be false. It is difficult to make general
recommendations as to how physicians should treat patients
with ADHD who they also suspect of misusing and/or
diverting stimulants. Physicians must use their best clinical
judgment to provide each of their patients with a treatment
plan that is best suited for their individual needs, while taking into consideration concerns regarding stimulant misuse
and diversion.
Although these findings have clinical relevance and
important implications, several methodological weaknesses
and limitations must be noted that limit our ability to make
generalizations on this topic. First, although our sample was
diverse in terms of age, gender, and patient volume, we cannot rule out sampling bias. For example, it is possible that
responders varied from non-responders with respect to
demographics or perceptions regarding misuse and/or diversion; this could not be evaluated with available data. In addition, our overall response rate was somewhat low, although
surveys of physicians tend to have lower response rates
(VanGeest, Johnson, & Welch, 2007) and the response rate
in this study is similar to that noted in other recent studies
(Bonevski, Magin, Horton, Foster, & Girgis, 2011). Because
our data were based on physician self-report, estimates of
the pervasiveness of diversion and/or misuse among their
own patients may be subject to cognitive bias (i.e., a halo
effect). Furthermore, there are many factors that might contribute to physician awareness of stimulant misuse and
diversion, including previous training on these issues, extent
of clinical experience, practice setting, previous exposure to
these issues through colleagues or media reports, and prescribing volume. It is particularly important to note that
almost half of physicians in our sample currently prescribe
stimulants to fewer than 30 adolescent patients, which might
have a significant impact on awareness. Our study design
also precludes us from confirming or rejecting the accuracy
of physician perceptions in this study. Also, physician perceptions of misuse and/or diversion might vary depending
on the specific medication formulation (e.g., Adderall,
Vyvanse, Concerta, etc.), but this study only inquired about
stimulant medications in general. Last, because this study
focused on pediatric subspecialists, our results may not be
generalizable to primary care pediatricians.
Findings from this study suggest several different follow-up studies. First, research is needed to determine
whether physician concerns about stimulant diversion influence their clinical management of adolescents with ADHD
(e.g., patient education, prescribing practices). Second,
investigators should explore whether physician concerns
about patients feigning ADHD symptoms to get stimulants
adversely influence clinical care. For example, whereas clinician skepticism may reduce over-diagnosis of ADHD,
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these suspicions may also pose obstacles to the accurate
diagnosis and treatment of youth who have ADHD but do
not present until adolescence. Research should also be done
to examine the impact of various factors on physician perceptions of stimulant misuse and diversion. For example, to
what extent do formal training, past clinical experience, and
prescribing volume influence the accuracy of physician perceptions? Finally, because this study focused on pediatric
subspecialists, a large-scale study assessing general pediatricians’ awareness of this issue is warranted.
The findings of this study—the first to evaluate the pervasiveness of stimulant misuse and diversion from a physician’s perspective—are concerning in several respects.
First, the fact that a majority of physicians in our sample do
indeed suspect illegal and potentially unsafe behavior by
their patients with ADHD adds to mounting evidence suggesting that non-medical use of stimulant medication is a
societal issue of escalating importance. Conversely, the
finding that a sizable number of pediatric subspecialists do
not suspect stimulant diversion or misuse among any of
their adolescent patients and do not believe diversion to be
common provides evidence that too many physicians are
unaware of this issue. This lack of awareness must be remedied through increased training and continuing education
efforts, as it is imperative that physicians be mindful of
these issues when treating youth with ADHD. Moreover,
given the health and legal consequences associated with
stimulant misuse and diversion, physicians must take
greater responsibility in the prevention of stimulant diversion and misuse by adolescents.
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